Cargando…

A comprehensive study on surveillance outcomes of a male population followed at a hereditary breast cancer high-risk consultation at a Portuguese tertiary hospital

INTRODUCTION: Men born with pathogenic/likely pathogenic variants in genes associated with the Hereditary Breast and Ovarian Cancer Syndrome have a higher risk to develop breast cancer and other cancers (such as prostate cancer) and should undergo adequate surveillance protocols in highly specialize...

Descripción completa

Detalles Bibliográficos
Autores principales: Oliveira, Maria João, Costa, Susy, Magalhães, André, Garrido, Luzia, Peleteiro, Bárbara, Fougo, José Luís, Castedo, Sérgio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10465621/
https://www.ncbi.nlm.nih.gov/pubmed/37347260
http://dx.doi.org/10.1007/s00432-023-04994-7
_version_ 1785098709672919040
author Oliveira, Maria João
Costa, Susy
Magalhães, André
Garrido, Luzia
Peleteiro, Bárbara
Fougo, José Luís
Castedo, Sérgio
author_facet Oliveira, Maria João
Costa, Susy
Magalhães, André
Garrido, Luzia
Peleteiro, Bárbara
Fougo, José Luís
Castedo, Sérgio
author_sort Oliveira, Maria João
collection PubMed
description INTRODUCTION: Men born with pathogenic/likely pathogenic variants in genes associated with the Hereditary Breast and Ovarian Cancer Syndrome have a higher risk to develop breast cancer and other cancers (such as prostate cancer) and should undergo adequate surveillance protocols in highly specialized Centers. METHODS: A retrospective study was conducted to assess these genetic variants’ epidemiological and phenotypical manifestations in male carriers, as well as the efficacy of the surveillance protocol and compliance toward it through a survey. During follow-up, a genetic panel for testing was implemented, the starting age for surveillance was delayed, and the six-month screening interval was extended to annual. RESULTS: A total of 104 men from a tertiary hospital’s High-Risk Consultation were included, 102 with positive genetic testing for BRCA1 (n = 31), BRCA2 (n = 55), both BRCA2 and another gene (n = 5), CDH1 (n = 2), CHEK2 (n = 4), NF1 (n = 1), RAD51C (n = 4), and an additional two men with no actionable genetic variant identified. The follow-up period ranged from 1 to 13 years, and only one man developed cancer. Survey responses from 48 men in active surveillance showed that more than half recognizes their carrier status and consequent surveillance impact on their life, including the risk of transmission to offspring, fear of future cancer, meaningful distress, and feeling of injustice. Biannual surveillance was not actively detecting more cancer disease cases, confirming the adequacy of the currently implemented protocol CONCLUSION: With support of Genetics to fulfill the current gaps in high-risk management, the proposed redefinition of surveillance protocol would adapt it to the population needs and concerns.
format Online
Article
Text
id pubmed-10465621
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-104656212023-08-31 A comprehensive study on surveillance outcomes of a male population followed at a hereditary breast cancer high-risk consultation at a Portuguese tertiary hospital Oliveira, Maria João Costa, Susy Magalhães, André Garrido, Luzia Peleteiro, Bárbara Fougo, José Luís Castedo, Sérgio J Cancer Res Clin Oncol Research INTRODUCTION: Men born with pathogenic/likely pathogenic variants in genes associated with the Hereditary Breast and Ovarian Cancer Syndrome have a higher risk to develop breast cancer and other cancers (such as prostate cancer) and should undergo adequate surveillance protocols in highly specialized Centers. METHODS: A retrospective study was conducted to assess these genetic variants’ epidemiological and phenotypical manifestations in male carriers, as well as the efficacy of the surveillance protocol and compliance toward it through a survey. During follow-up, a genetic panel for testing was implemented, the starting age for surveillance was delayed, and the six-month screening interval was extended to annual. RESULTS: A total of 104 men from a tertiary hospital’s High-Risk Consultation were included, 102 with positive genetic testing for BRCA1 (n = 31), BRCA2 (n = 55), both BRCA2 and another gene (n = 5), CDH1 (n = 2), CHEK2 (n = 4), NF1 (n = 1), RAD51C (n = 4), and an additional two men with no actionable genetic variant identified. The follow-up period ranged from 1 to 13 years, and only one man developed cancer. Survey responses from 48 men in active surveillance showed that more than half recognizes their carrier status and consequent surveillance impact on their life, including the risk of transmission to offspring, fear of future cancer, meaningful distress, and feeling of injustice. Biannual surveillance was not actively detecting more cancer disease cases, confirming the adequacy of the currently implemented protocol CONCLUSION: With support of Genetics to fulfill the current gaps in high-risk management, the proposed redefinition of surveillance protocol would adapt it to the population needs and concerns. Springer Berlin Heidelberg 2023-06-22 2023 /pmc/articles/PMC10465621/ /pubmed/37347260 http://dx.doi.org/10.1007/s00432-023-04994-7 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Research
Oliveira, Maria João
Costa, Susy
Magalhães, André
Garrido, Luzia
Peleteiro, Bárbara
Fougo, José Luís
Castedo, Sérgio
A comprehensive study on surveillance outcomes of a male population followed at a hereditary breast cancer high-risk consultation at a Portuguese tertiary hospital
title A comprehensive study on surveillance outcomes of a male population followed at a hereditary breast cancer high-risk consultation at a Portuguese tertiary hospital
title_full A comprehensive study on surveillance outcomes of a male population followed at a hereditary breast cancer high-risk consultation at a Portuguese tertiary hospital
title_fullStr A comprehensive study on surveillance outcomes of a male population followed at a hereditary breast cancer high-risk consultation at a Portuguese tertiary hospital
title_full_unstemmed A comprehensive study on surveillance outcomes of a male population followed at a hereditary breast cancer high-risk consultation at a Portuguese tertiary hospital
title_short A comprehensive study on surveillance outcomes of a male population followed at a hereditary breast cancer high-risk consultation at a Portuguese tertiary hospital
title_sort comprehensive study on surveillance outcomes of a male population followed at a hereditary breast cancer high-risk consultation at a portuguese tertiary hospital
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10465621/
https://www.ncbi.nlm.nih.gov/pubmed/37347260
http://dx.doi.org/10.1007/s00432-023-04994-7
work_keys_str_mv AT oliveiramariajoao acomprehensivestudyonsurveillanceoutcomesofamalepopulationfollowedatahereditarybreastcancerhighriskconsultationataportuguesetertiaryhospital
AT costasusy acomprehensivestudyonsurveillanceoutcomesofamalepopulationfollowedatahereditarybreastcancerhighriskconsultationataportuguesetertiaryhospital
AT magalhaesandre acomprehensivestudyonsurveillanceoutcomesofamalepopulationfollowedatahereditarybreastcancerhighriskconsultationataportuguesetertiaryhospital
AT garridoluzia acomprehensivestudyonsurveillanceoutcomesofamalepopulationfollowedatahereditarybreastcancerhighriskconsultationataportuguesetertiaryhospital
AT peleteirobarbara acomprehensivestudyonsurveillanceoutcomesofamalepopulationfollowedatahereditarybreastcancerhighriskconsultationataportuguesetertiaryhospital
AT fougojoseluis acomprehensivestudyonsurveillanceoutcomesofamalepopulationfollowedatahereditarybreastcancerhighriskconsultationataportuguesetertiaryhospital
AT castedosergio acomprehensivestudyonsurveillanceoutcomesofamalepopulationfollowedatahereditarybreastcancerhighriskconsultationataportuguesetertiaryhospital
AT oliveiramariajoao comprehensivestudyonsurveillanceoutcomesofamalepopulationfollowedatahereditarybreastcancerhighriskconsultationataportuguesetertiaryhospital
AT costasusy comprehensivestudyonsurveillanceoutcomesofamalepopulationfollowedatahereditarybreastcancerhighriskconsultationataportuguesetertiaryhospital
AT magalhaesandre comprehensivestudyonsurveillanceoutcomesofamalepopulationfollowedatahereditarybreastcancerhighriskconsultationataportuguesetertiaryhospital
AT garridoluzia comprehensivestudyonsurveillanceoutcomesofamalepopulationfollowedatahereditarybreastcancerhighriskconsultationataportuguesetertiaryhospital
AT peleteirobarbara comprehensivestudyonsurveillanceoutcomesofamalepopulationfollowedatahereditarybreastcancerhighriskconsultationataportuguesetertiaryhospital
AT fougojoseluis comprehensivestudyonsurveillanceoutcomesofamalepopulationfollowedatahereditarybreastcancerhighriskconsultationataportuguesetertiaryhospital
AT castedosergio comprehensivestudyonsurveillanceoutcomesofamalepopulationfollowedatahereditarybreastcancerhighriskconsultationataportuguesetertiaryhospital